This article was downloaded by: On: 23 January 2011 Access details: Access Details: Free Access Publisher Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Journal of Carbohydrate Chemistry

Publication details, including instructions for authors and subscription information: http://www.informaworld.com/smpp/title~content=t713617200

Synthesis of Substituted 1-\C\-Phenyl-D-Tetritols and 1-C-(1*H*-Pyrazol-4-yl)-D-tetritols by Ring Transformation of 2-Formylglycals

Alina Montero^{ab}; Manfred Michalik^e; Holger Feist^a; Helmut Reinke^a; Ivo Rudloff^{ad}; Klaus Peseke^a ^a Fachbereich Chemie, Universität Rostock, Rostock, Germany ^b Centro de Bioactivos Químicos, Universidad Central de Las Villas, Santa Clara, Cuba ^c Leibniz-Institut für Organische Katalyse, Rostock, Germany ^d Oswel Research Products Ltd., Lab 5005 — Medical and Biological Science Building, University of Southampton-Boldrewood, Southampton, UK

Online publication date: 28 November 2004

To cite this Article Montero, Alina , Michalik, Manfred , Feist, Holger , Reinke, Helmut , Rudloff, Ivo and Peseke, Klaus(2004) 'Synthesis of Substituted 1-|C|-Phenyl-D-Tetritols and 1-C-(1*H*-Pyrazol-4-yl)-D-tetritols by Ring Transformation of 2-Formylglycals', Journal of Carbohydrate Chemistry, 23: 5, 313 – 324

To link to this Article: DOI: 10.1081/CAR-200035732 URL: http://dx.doi.org/10.1081/CAR-200035732

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

Synthesis of Substituted 1-\C\-Phenyl-D-Tetritols and 1-C-(1H-Pyrazol-4-yl)-D-tetritols by Ring Transformation of 2-Formylglycals^{#,‡}

Alina Montero,^{1,2} Manfred Michalik,³ Holger Feist,¹ Helmut Reinke,¹ Ivo Rudloff,^{1,4} and Klaus Peseke^{1,*}

 ¹Fachbereich Chemie, Universität Rostock, Rostock, Germany
 ²Centro de Bioactivos Químicos, Universidad Central de Las Villas, Santa Clara, Cuba
 ³Leibniz-Institut für Organische Katalyse, Rostock, Germany
 ⁴Oswel Research Products Ltd., Lab 5005 — Medical and Biological Science Building, University of Southampton-Boldrewood, Southampton, UK

CONTENTS

	ABSTRACT 314
I.	INTRODUCTION
II.	RESULTS AND DISCUSSION
III.	EXPERIMENTAL 317 A. General Procedures 317
	ACKNOWLEDGMENTS
	REFERENCES

[#]Dedicated to Professor Dr. Dr. hc. Adolf Zschunke on the occasion of his 65th birthday.

[‡]Presented at the XXth International Carbohydrate Symposium, Hamburg, Germany, 2000.

*Correspondence: Klaus Peseke, Fachbereich Chemie, Universität Rostock, D-18051, Rostock, Germany; Fax: +49-381-498-6412; E-mail: klaus.peseke@chemie.uni-rostock.de.

313

DOI: 10.1081/CAR-200035732 Copyright © by Marcel Dekker, Inc. 0732-8303 (Print); 1532-2327 (Online) www.dekker.com

Request Permissions / Order Reprints powered by **RIGHTSLINK**

ABSTRACT

2-Formylglycals **1a,b** reacted with dialkyl 3-oxoglutarates in the presence of base to furnish the 5-[(1R,2R(S),3R)-1,2,4-tris(benzyloxy)-3-hydroxy-butyl]-2-hydroxy-isophthalic acid dialkyl esters**2a-d**. Treatment of**1a,b**with hydrazine derivatives afforded the substituted 1,2,4-tri-*O*-benzyl-1*C*-(1*H*-pyrazol-4-yl)-D-tetritols**5a-d**. Deprotection of**5a,b**was achieved with Pd/H₂ to yield the 1*C*-(1-methyl-1*H*-pyrazol-4-yl)-D-tetritols**6a,b**.

Key Words: Formylglycals; Acyclo-C-nucleosides; Pyrazoles; Isophthalic acid esters; Ring transformation; Push-pull alkenes.

INTRODUCTION

Owing to their potential biological properties, substantial efforts have been devoted to the synthesis of modified nucleosides since their discovery.^[1-8] In order to obtain less toxic, less susceptible to viral resistance or more active compounds of this type new syntheses have been developed. Furthermore, the syntheses of heterocycles with a polyhydroxyalkyl chain have attracted great interest in synthetic organic chemistry.^[9-11]

In earlier studies, we investigated the ring transformations of *C*-branched, unsaturated sugars with *push-pull* functionalisation to furnish a new class of modified acyclo-*C*-nucleosides.^[12–15] We describe in this paper the reactions of 2-formylglycals using 1,3-*C*,*C*'- and 1,2-*N*,*N*'-dinucleophiles to obtain new acyclo-*C*-nucleoside analogues.

RESULTS AND DISCUSSION

Because of their *push-pull* activated carbon-carbon double bond, ^[16-18] 2-formylglycals **1a**,**b**^[19] synthesised by a Vilsmeier–Haack reaction of *O*-benzyl protected glycals are a versatile class of compounds, which should allow the nucleophilic attack of dinucleophiles at C-1 under ring opening of the glycals followed by cyclisation involving the formyl group. Treatment of **1a**,**b** under reflux with dialkyl 3-oxoglutarates as 1,3-*C*,*C*'-dinucleophiles and potassium carbonate in presence of crown ether afforded the expected 5-[(1R,2R(S),3R)-1,2,4-tris(benzyloxy)-3-hydroxy-butyl]-2-hydroxyisophthalic acid dialkyl esters**2a**–**d**in such ring transformation reactions (Sch. 1).

The NMR spectra of these compounds showed the absence of signals for the formyl group and the presence of two hydroxy and alkoxycarbonyl groups. All the other analytical data are in accordance with the proposed open-chain sugar structures as well. The NMR signals of the carbon and hydrogen atoms could unambiguously be assigned with ¹³C, ¹H correlation experiments confirming the postulated structures.

Furthermore, an x-ray structure of compound 2d could be obtained. An ORTEP drawing is shown in Fig. 1.

The crystal structure of 2d is dominated by the formation of hydrogen bridges. The infinite chains of molecules along the *b* axis are formed by bridges between the hydroxyl group at C-3 and one of the carbonyl groups of a neighbouring molecule. The other hydroxyl group at C-4' is involved in an intramolecular hydrogen bridge towards one of



Scheme 1.

the carbonyl groups in the same molecule. This phenomenon helps to explain the complex infrared spectra of **2d**.

In order to obtain benzofuran derivatives, we carried out the reactions of 2c,d with ethyl chloroacetate in the presence of potassium carbonate in acetone. After a first step, the 5-[(1R,2R(S),3R)-1,2,4-tris(benzyloxy)-3-hydroxy-butyl]-2-ethoxycarbo-nylmethoxy-isophthalic acid diethyl esters **3a,b** were isolated. However, the desired heterocyclisation to yield the corresponding 5-[(1R,2R(S),3R)-1,2,4-tris(benzyloxy)-3-hydroxy-butyl]-3-hydroxy-benzo[*b*]furan-2,7-dicarboxylic acid diethyl esters could not be achieved.



Figure 1. ORTEP drawing of 2d.

The *push-pull* functionality of **1a,b** should also allow reactions with 1,2-*N*,*N'*-dinucleophiles. In analogy to similar *push-pull* compounds,^[17-19] the nucleophilic attack of hydrazine derivatives at C-1 was accompanied by cyclisation involving the formyl group to furnish the corresponding pyrazole ring. In this manner, treatment of the starting materials with methylhydrazine and 2-hydrazinoethanol, respectively, under reflux afforded the substituted (1*R*)-1,2,4-tri-*O*-benzyl-1-*C*-(1*H*-pyrazol-4-yl)-D-alditols **4a-d**. The IR and the ¹³C NMR spectra of these products showed the absence of signals for the formyl group. Furthermore, the successful ring transformation was proven by observing the typical long range coupling between the pyrazol protons H-3' and H-5' (⁴*J* ~ 0.6 Hz for **4a,b** and 0.9 Hz for **4c,d**, respectively) in the ¹H NMR spectrum due to the W-arrangement. Furthermore, in the ¹H NMR spectra of **4c, d** appeared an additional signal for an OH group. ¹³C, ¹H and ¹H, ¹H correlation spectra allowed the unambiguous assignment of all signals for the proposed structures. Thus, the distinction of H-3' and H-5' was possible by a correlation found for H-5' and N–Me in the NOESY spectrum of **4b**.

Finally, we examined the deprotection of the synthesised systems for two examples. The catalytic hydrogenation^[20] of compounds 4a,b was successful and afforded the

Ring Transformation of 2-Formylglycals

acyclo-*C*-nucleoside analogues **5a,b** in very good yields. In the ¹H NMR of **5a,b** spectra signals for benzyl groups were absent and instead four signals for OH groups were found.

In conclusion, we described here starting from *push-pull* functionalised unsaturated sugars a simple method to prepare aryl and hetaryl *C*-substituted additoles to be considered as new acyclo-*C*-nucleoside analogues.

EXPERIMENTAL

General Procedures

TLC was carried out on silica gel 60 GF₂₅₄ (Merck) with detection by UV light ($\lambda = 254 \text{ nm}$) and/or by charring with 5% sulfuric acid in methanol. Silica gel 60 (63–200 mesh) (Merck) was used for column chromatography. Melting points were determined by using a Boetius melting point apparatus and are corrected. Specific rotations were determined with a Polar LµP (IBZ Messtechnik). IR spectra were recorded with a Nicolet 205 FT-IR spectrometer. ¹H NMR (300.13 and 250.13 MHz, respectively) and ¹³C NMR (75.5 and 62.9 MHz, respectively) spectra were recorded on Bruker instruments ARX 300 and AC 250, respectively, with CDCl₃ or DMSO-*d*₆ as solvent. The calibration of spectra was carried out on TMS (internal, ¹H) and solvent (¹³C) signals (δ^{1} H TMS = 0; δ^{13} C CDCl₃ = 77.0, DMSO-*d*₆ = 39.7). The ¹H and¹³C NMR signals were assigned by DEPT and/or two-dimensional ¹H, ¹³C correlation experiments. The mass spectra were recorded on an AMD 402/3 spectrometer (AMD Intectra GmbH). Elemental analysis was performed on a Leco CHNS-932 instrument. For chromatography Merck silica gel 60 (230–400 mesh) was used.

5-[(1R,2R,3R)-1,2,4-Tris(benzyloxy)-3-hydroxy-butyl]-2-hydroxy-isophthalic acid **dimethyl ester (2a).** Potassium carbonate (60 mg), 18-crown-6 (50 mg), and dimethyl 3-oxoglutarate (0.043 mL, 0.3 mmol) were added to a solution of 2-formyl-3,4,6-tri-O-benzyl-D-glucal 1a (100 mg, 0.225 mmol) in THF (5 mL). The mixture was then heated under reflux and stirred for 6 hr. After this time another amount of dimethyl 3-oxoglutarate (0.043 mL, 0.3 mmol) was added. The solution was refluxed again and stirring was continued up to the disappearance of 1a (7 hr, TLC control). After filtration, the solvent was evaporated and the residue purified by column chromatography (toluene/EtOAc 9:1). Compound **2a** was isolated as a colourless syrup. Yield 80 mg (59%); $\left[\alpha\right]_{D}^{23} - 50.3$ $(c = 1, \text{ CHCl}_3); R_f 0.24$ (toluene/EtOAc 9:1). IR (film), (cm⁻¹): 3446 (OH); 1732, 1720, 1678 (C=O); 1613 (C=C). ¹H NMR (300.13 MHz, CDCl₃), δ 1.92 (br, 1H, OH-3'); 3.50 (dd, 1H, ${}^{3}J_{1,2} = 3.0$ Hz, ${}^{3}J_{2,3} = 7.3$ Hz, H-2'); 3.52–3.56 (m, AB part of ABX, 2H, H-4'a,b); 3.84 (s, 6H, Me); 3.94 (m, 1H, H-3'); 3.98 (d, 1H, ${}^{2}J = 11.0$ Hz, CHHPh); 4.17 (d, 1H, ${}^{2}J = 11.8$ Hz, CHHPh); 4.26 (d, 1H, ${}^{2}J = 11.0$ Hz, CHHPh); 4.43 (s, 2H, CH₂Ph); 4.47 (d, 1H, ${}^{2}J = 11.8$ Hz, CHHPh); 4.61 (d, 1H, H-1'); 6.91–6.97 (m, 2H, Ph); 7.07–7.14 (m, 3H, Ph); 7.17–7.30 (m, 10H, Ph); 7.99 (s, 2H, H-4, H-6); 11.69 (s, 1H, OH-2). ¹³C NMR (75.5 MHz, CDCl₃), δ 52.3 (Me); 70.1 (C-3'); 70.9, 71.3, 73.5, 74.6 (C-4', CH₂Ph); 78.7 (C-1'); 82.0 (C-2'); 116.4 (C-1, C-3); 127.6, 127.8 (p-Ph); 128.0, 128.1, 128.3, 128.4, 128.5 (o-, m-,p-Ph); 129.0 (C-5); 135.6 (C-4, C-6); 137.4 (2x), 137.8 (i-Ph); 161.1 (C-2); 167.9 (C=O). MS (FAB positive, NBA/NaCl), m/z (%): 623 (100) [M + Na]⁺.

Anal. calcd for C₃₅H₃₆O₉(600.65): C, 69.99; H, 6.04. Found: C, 69.96; H, 5.79.

5-[(1R,2S,3R)-1,2,4-Tris(benzyloxy)-3-hydroxy-butyl]-2-hydroxy-isophthalic acid dimethyl ester (2b). The reaction of 1b with dimethyl 3-oxoglutarate was carried out as described above for the preparation of 2a. Compound 2b was isolated as a white solid after recrystallisation from *n*-heptane. Yield 68 mg (50%); mp 78-81°C; $[\alpha]_{23}^{23}$ $-29.0 \ (c = 1, \text{CHCl}_3); R_f \ 0.24 \ (\text{toluene/EtOAc } 9:1). \text{ IR (KBr)}, \nu \ (\text{cm}^{-1}): 3414 \ (\text{OH});$ 1742, 1705, 1682 (C=O); 1610 (C=C). ¹H NMR (300.13 MHz, CDCl₃), δ 2.00 (br, 1H, OH-3'); 3.45 (dd, 1H, ${}^{2}J_{4a,4b} = 9.5$ Hz, ${}^{3}J_{3,4a} = 6.1$ Hz, H-4'a); 3.51 (dd, 1H, ${}^{3}J_{3,4b} = 6.1 \text{ Hz}, \text{ H-4'b}); 3.54 \text{ (dd, 1H, } {}^{3}J_{1,2} = 8.1 \text{ Hz}, {}^{3}J_{2,3} = 2.2 \text{ Hz}, \text{ H-2'}); 3.86$ (s, 6H, Me); 3.86 (d, 1H, ${}^{2}J = 10.8$ Hz, CHHPh); 4.10 (dt, 1H, H-3'); 4.16 (d, 1H, $^{2}J = 10.8$ Hz, CHHPh); 4.21 (d, 1H, $^{2}J = 11.6$ Hz, CHHPh); 4.36 (d, 1H, $^{2}J = 11.6$ Hz, CHHPh); 4.45 (d, 1H, H-1'); 4.43, 4.47 (q(AB), 2H, ${}^{2}J = 11.9$ Hz, CH₂Ph); 6.80–6.88 (m, 2H, Ph); 7.05-7.14 (m, 3H, Ph); 7.15-7.31 (m, 10H, Ph); 7.98 (s, 2H, H-4, H-6); 11.69 (s, 1H, OH-2). ¹³C NMR (62.9 MHz, CDCl₃), δ 52.4 (Me); 69.4 (C-3'); 71.0 (CH₂Ph); 71.1 (C-4'); 73.5, 74.4 (CH₂Ph); 79.4 (C-1'); 81.1 (C-2'); 116.3 (C-1, C-3); 127.7-128.4 (Ph); 129.7 (C-5); 135.6 (C-4, C-6); 137.0, 137.4, 137.8 (i-Ph); 161.2 (C-2); 167.8 (C=O). MS (FAB positive, NBA/NaCl), m/z (%): 623 (100) $[M + Na]^+$.

Anal. calcd for C35H36O9(600.65): C, 69.99; H, 6.04. Found: C, 70.01; H, 6.16.

5-[(1R,2R,3R)-1,2,4-Tris(benzyloxy)-3-hydroxy-butyl]-2-hydroxy-isophthalic acid diethyl ester (2c). Diethyl 3-oxoglutarate (0.108 mL, 0.6 mmol) and 2-formyl-3,4,6-tri-O-benzyl-D-glucal 1a (100 mg, 0.225 mmol) were reacted as described for the preparation of 1a. Compound 2c was isolated as a colourless syrup. Yield 78 mg (55%); $[\alpha]_{\rm D}^{24} - 33.7$ $(c = 1, \text{CHCl}_3); R_f 0.29 \text{ (toluene/EtOAc 9:1). IR (film)}, \nu (\text{cm}^{-1}): 3429 \text{ (OH)}; 1731,$ 1717, 1672 (C=O); 1612 (C=C). ¹H NMR (300.13 MHz, CDCl₃), δ 1.31 (t, 6H, ${}^{3}J = 7.3$ Hz, Me); 2.42 (br, 1H, OH-3'); 3.49 (dd, 1H, ${}^{3}J_{1,2} = 3.0$ Hz, ${}^{3}J_{2,3} = 7.6$ Hz, H-2'); 3.52-3.60 (m, AB part of ABX, 2H, H-4'a,b); 3.96 (d, 1H, ${}^{2}J = 11.0$ Hz, CHHPh); 3.97 (m, 1H, H-3); 4.18 (d, 1H, ${}^{2}J = 11.8$ Hz, CHHPh); 4.22 (d, 1H, ${}^{2}J =$ 11.0 Hz, CHHPh); 4.32 (m, 4H, CH₂); 4.44 (s, 2H, CH₂Ph); 4.48 (d, 1H, ${}^{2}J = 11.8$ Hz, CHHPh); 4.63 (d, 1H, H-1'); 6.90-6.96 (m, 2H, Ph); 7.06-7.13 (m, 3H, Ph); 7.14-7.31 (m, 10H, Ph); 7.98 (s, 2H, H-4, H-6); 11.76 (s, 1H, OH-2). ¹³C NMR (75.5 MHz, CDCl₃), δ 14.2 (Me); 61.5 (CH₂); 70.1 (C-3'); 70.9, 71.3, 73.5, 74.7 (C-4', CH₂Ph); 78.6 (C-1'); 82.0 (C-2'); 116.7 (C-1, C-3); 127.6, 127.9 (p-Ph); 128.0, 128.1, 128.4, 128.4, 128.5 (o-, m-, p-Ph); 128.9 (C-5); 135.2 (C-4, C-6); 137.4, 137.5, 137.8 (*i*-Ph); 161.2 (C-2); 167.5 (C=O). MS (CI, *iso*-butane), m/z (%): 629 (0.5) [M + H]⁺, 91 (100).

Anal. calcd for C₃₇H₄₀O₉(628.71): C, 70.68; H, 6.41. Found: C, 70.74; H, 6.32.

5-[(*IR*,2*S*,3*R*)-1,2,4-Tris(benzyloxy)-3-hydroxy-butyl]-2-hydroxy-isophthalic acid diethyl ester (2d). The reaction of 1b with diethyl 3-oxoglutarate was carried out as described above for the preparation of 2c. Recrystallisation from dichloromethane/ *n*-heptane yielded 2d as colourless crystals. Yield 76 mg (54%); mp 78–81°C; $[\alpha]_D^{24} - 23.4$ (*c* = 0.5, CHCl₃); *R*_f 0.33 (toluene/EtOAc 9:1). IR (KBr), ν (cm⁻¹): 3429 (OH); 1732, 1708, 1665 (C=O); 1612 (C=C). ¹H NMR (250.13 MHz, CDCl₃), δ 1.34 (t, 6H, ³*J* = 7.3 Hz, Me); 2.53 (br, 1H, OH-3'); 3.45 (dd, 1H, ²*J*_{4a,4b} = 9.5 Hz, ³*J*_{3,4a} = 6.1 Hz, H-4'a); 3.52 (dd, 1H, ³*J*_{3,4b} = 6.1 Hz, H-4'b); 3.53 (dd, 1H, ³*J*_{1,2} = 8.2 Hz, ³*J*_{2,3} = 2.1 Hz, H-2'); 3.82 (d, 1H, ²*J* = 11.0 Hz, C*H*HPh); 4.12 (d, 1H, ²*J* = 11.0 Hz, C*H*HPh); 4.14 (br m, 1H, H-3'); 4.21 (d, 1H, ²*J* = 11.5 Hz, C*H*HPh); 4.34 (q, 4H, CH₂); 4.36 (d, 1H, ²*J* = 11.5 Hz, C*H*HPh); 4.46 (d, 1H, H-1'); 4.45, 4.48

Ring Transformation of 2-Formylglycals

(q(AB), 2H, ${}^{2}J$ = 11.8 Hz, CH₂Ph); 6.80–6.88 (m, 2H, Ph); 7.05–7.14 (m, 3H, Ph); 7.15–7.30 (m, 10H, Ph); 7.99 (s, 2H, H-2', H-6'); 11.82 (s, 1H, OH-4'). 13 C NMR (62.9 MHz, CDCl₃), δ 14.2 (Me); 61.6 (CH₂); 69.4 (C-3'); 71.0, 71.2, 73.5, 74.4 (C-4', CH₂Ph); 79.4 (C-1'); 81.1 (C-2'); 116.6 (C-1, C-3); 127.7–128.5 (Ph); 129.6 (C-5); 135.3 (C-4, C-6); 137.0, 137.4, 137.9 (*i*-Ph); 161.4 (C-2); 167.4 (C=O). MS, (CI, *iso*-butane), m/z (%): 629 (0.5) [M + H]⁺.

Anal. calcd for C₃₇H₄₀O₉(628.71): C, 70.68; H, 6.41. Found: C, 70.78; H, 6.66.

Compound 2d was subjected to x-ray analysis at 293 K and wavelength 0.71073 Å. The crystal was sealed onto a glass fiber and mounted on a Bruker P4 automated four circle diffractometer. The structure was solved by direct methods (XS program for crystal structure solution, version 4.2 for MS-DOS, copyright Bruker Analytical X-ray Inst. Inc.) and refined by the full-matrix least squares method on F^2 (SHELXL-97; G.M. Sheldrick, Universität Göttingen, 1997). Non-H atoms were refined with anisotropic displacement parameters. All hydrogen atoms were placed into theoretical positions and were refined by using the riding model. **2d**, $(C_{37}H_{40}O_9)$; formula weight = 628.69; crystal system: monoclinic; space group: $P2_1$; unit cell dimensions: a = 11.781(3) Å, b = 10.783(2) Å, c = 13.171(2) Å, $\hat{\beta} = 92.58(2)^{\circ}$; volume: 1671.5(6) Å³; Z = 2; density (calculated): 1.249 Mg/m³; absorption coefficient: 0.089 mm⁻¹; F(000) = 668; crystal size: $0.76 \times 0.63 \times 0.53 \text{ mm}^3$; Θ range for data collection: 2.270 to 22.00°; index ranges: $-12 \le h \le 12$, $-11 \le k \le 11$, $-13 \le l \le 13$; reflections collected: 4560; independent reflections: 4075 [R(int) = 0.0489]; completeness to $\Theta = 22.00^{\circ}$: 99.8%; absorption correction: none; data/restraints/parameters: 4075/1/417; goodness-of-fit on F^2 : 1.028; final R indices $[I > 2\sigma(I)]$: $R_1 = 0.0504$, $wR_2 = 0.1311$; R indices (all data): R1 = 0.0565, wR2 = 0.1377; absolute structure parameter: 0.1(13); largest different peak and hole: 0.187 and $-0.161 \text{ e} \text{ Å}^{-3}$.

CCDC-190061 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge via www.ccdc.cam.ac.uk/conts/retrieving. html (or from the CCDC, 12 Union Road, Cambridge CB2 1EZ, UK; Fax: +44 1223 336033; E-mail: deposit@ccdc.cam.ac.uk).

5-[(1R,2R,3R)-1,2,4-Tris(benzyloxy)-3-ethoxycarbonylmethoxy-butyl]-2-hydroxyisophthalic acid diethyl ester (3a). Ethyl chloroacetate (0.017 mL, 0.159 mmol) and potassium carbonate (43 mg) were added to a solution of 2c (100 mg, 0.159 mmol) in acetone (5 mL). The mixture was then heated under reflux and stirring for 5 hr. After this time, the solution was filtered, the solvent was evaporated, and the residue purified by column chromatography (toluene/EtOAc 9:1). Compound 3a was obtained as a colourless syrup.

Yield 8 mg (72%); $[\alpha]_D^{21} - 35.5$ (c = 0.4, CHCl₃); $R_f 0.22$ (toluene/EtOAc 5 : 1). IR (film), ν (cm⁻¹): 3514 (OH); 1763, 1731 (C=O). ¹H NMR (250.13 MHz, CDCl₃), δ 1.25 (t, 3H, ³J = 7.1 Hz, CH₃CH₂OC(=O)CH₂); 1.28 (t, 6H, ³J = 7.1 Hz, CH₃CH₂OC(=O)); 1.97 (br, 1H, OH-3'); 3.50 (dd, 1H, ³ $J_{1,2} = 2.8$ Hz, ³ $J_{2,3} = 7.6$ Hz, H-2'); 3.55 (m, 2H, H-4'a,b); 3.86 (d, 1H, ²J = 10.7 Hz, CHHPh); 3.95 (dt, 1H, ³ $J_{3,4a} = {}^{3}J_{3,4b} = 4.0$ Hz, H-3'); 4.12 (d, 1H, ²J = 10.7 Hz, CHHPh); 4.19 (d, 1H, ²J = 11.6 Hz, CHHPh); 4.24 (q, 2H, CH₃CH₂OC(=O)CH₂); 4.28 (q, 4H, CH₃CH₂OC(=O)); 4.43 (s, 2H, CH₂Ph); 4.50 (d, 1H, ²J = 11.6 Hz, CHHPh); 4.70 (d, 1H, H-1'); 4.75 (s, 2H, CH₃CH₂-OC(=O)CH₂); 6.86–6.96 (m, 2H, Ph); 7.06–7.34 (m, 13H, Ph); 7.94 (s, 2H, H-4, H-6). ¹³C NMR (62.9 MHz, CDCl₃), δ 14.1 (CH₃CH₂OC(=O)); 14.2 (CH₃CH₂-OC(=O)CH₂); 61.0 (CH₃CH₂OC(=O)CH₂); 61.5 (CH₃CH₂OC(=O)); 69.9 (C-3'); 70.8, 71.6, 73.5, 74.6 (C-4', CH₂Ph); 72.2 (CH₃CH₂OC(=O)CH₂); 78.6 (C-1'); 81.8 (C-2'); 127.2 (C-1, C-3); 127.7–128.5 (Ph); 134.0 (C-4, C-6); 135.6 (C-5); 137.2, 137.3, 137.7 (*i*-Ph); 156.5 (C-2); 165.1 (CH₃CH₂OC(=O)); 168.7 (CH₃CH₂OC(=O)CH₂). MS (CI, *iso*-butane), m/z (%): 715 (3) [M + H]⁺.

HRMS Calcd for C₄₁H₄₆O₁₁-OCH₂Ph: 669.26996, Found: 669.26870.

5-[(1R,2S,3R)-1,2,4-Tris(benzyloxy)-3-ethoxycarbonylmethoxy-butyl]-2-hydroxyisophthalic acid diethyl ester (3b). The reaction of 3b with chloroacetic acid ethylester was carried out as described above for the preparation of **3a** yielding a colourless syrup. Yield 78 mg (69%); $[\alpha]_{D}^{21}$ – 19.7 (c = 1, CHCl₃); $R_{f}0.25$ (toluene/EtOAc 5:1). IR (film), ν (cm⁻¹): 3514 (OH); 1763, 1731 (C=O). ¹H NMR (300.13 MHz, CDCl₃), δ 1.25 (t, 3H, ${}^{3}J = 7.1$ Hz, CH₃CH₂OC(=O)CH₂); 1.29 (t, 6H, ${}^{3}J = 7.1$ Hz, CH₃CH₂OC(=O)); 2.22 (br, 1H, OH-3'); 3.42 (dd, 1H, ${}^{2}J_{4a,4b} = 9.4$ Hz, ${}^{3}J_{3,4a} = 6.2$ Hz, H-4'a); 3.50 (dd, 1H, ${}^{3}J_{3,4b} = 6.0$ Hz, H-4'b); 3.53 (dd, 1H, ${}^{3}J_{1,2} = 8.3$ Hz, ${}^{3}J_{2,3} = 2.0$ Hz, H-2'); 2.74 (d, 1H, ${}^{2}J = 10.7$ Hz, CHHPh); 4.04 (d, 1H, ${}^{2}J = 10.7$ Hz, CHHPh); 4.10–4.22 (m, 2H, H-3', CHHPh); 4.23 (q, 2H, CH₃CH₂OC(=O)CH₂); 4.29 (q, 4H, CH₃CH₂OC(=O)); 4.37 (d, 1H, ${}^{2}J = 11.3$ Hz, CHHPh); 4.42, 4.47 (q, AB), 2H, ${}^{2}J = 11.9$ Hz, CH₂Ph); 4.54 (d, 1H, H-1'); 4.73 (s, 2H, CH₃CH₂OC(=O)CH₂); 6.82-6.86 (m, 2H, Ph); 7.05-7.30 (m, 13H, Ph); 7.95 (s, 2H, H-4, H-6). ¹³C NMR (75.5 MHz, CDCl₃), δ 14.1 (CH₃CH₂OC(=O)); 14.2 (CH₃CH₂OC(=O)CH₂); 61.0 (CH₃CH₂OC(=O)CH₂); 61.5 (CH₃CH₂OC(=O)); 69.3 (C-3'); 71.1, 71.3, 73.5, 74.4 (C-4', CH₂Ph); 72.2 (CH₃CH₂-OC(=O)CH₂); 79.3 (C-1'); 81.1 (C-2'); 127.2 (C-1, C-3); 127.7-128.4 (Ph); 134.3 (C-4, C-6); 136.2 (C-5); 136.9, 137.3, 137.8 (*i*-Ph); 156.6 (C-2); 165.0 (CH₃CH₂OC(=O)); 168.7 (CH₃CH₂OC(=O)CH₂). MS, (CI, *iso*-butane), m/z (%): 715 (2) [M + H]⁺.

HRMS calcd for C₄₁H₄₆O₁₁–OCH₂Ph: 669.26996, Found: 669.26840.

(1R)-1,2,4-Tri-O-benzyl-1-C-(1-methyl-1H-pyrazol-4-yl)-D-erythritol (4a). A solution of 1a (100 mg, 0.225 mmol) in ethanol (5 mL) and methylhydrazine (0.024 mL, 0.45 mmol) was 10 min refluxed under stirring. After this time the solvent was evaporated and the residue purified by column chromatography (toluene/EtOAc 1:1). Compound 5a was isolated as a colourless syrup.

Yield 85 mg (80%); $[\alpha]_{D}^{23} - 29.9$ (c = 0.5, CHCl₃); $R_f 0.40$ (toluene/EtOAc 1:1). IR (film), ν (cm⁻¹): 3423 (OH). ¹H NMR (300.13 MHz, CDCl₃), δ 2.76 (br, 1H, OH-3); 3.53–3.62 (m, AB-part of ABX, 2H, H-4a,b); 3.68 (dd, 1H, ³ $J_{1,2} = 4.1$ Hz, ³ $J_{2,3} = 6.7$ Hz, H-2); 3.87 (s, 3H, Me); 3.93 (m, 1H, H-3); 4.30 (d, 1H, ²J = 11.9 Hz, CHHPh); 4.45 (d, 1H, ²J = 11.3 Hz, CHHPh); 4.50 (s, 2H, CH₂Ph); 4.51 (d, 1H, ²J = 11.3 Hz, CHHPh); 4.45 (d, 1H, ²J = 11.9 Hz, CHHPh); 4.67 (d, 1H, H-1); 7.16–7.37 (m, 15H, Ph); 7.28 (d, 1H, H-5'); 7.47 (d, 1H, ⁴ $J_{3',5'} = 0.6$ Hz, H-3'). ¹³C NMR (75.5 MHz, CDCl₃), δ 38.9 (Me); 70.4 (C-3); 70.7 (CH₂Ph); 71.0 (C-4); 73.4, 74.3 (CH₂Ph); 73.4 (C-1); 81.4 (C-2); 119.0 (C-4'); 127.7, 127.7, 127.8 (*p*-Ph); 127.9, 128.0, 128.1, 128.3, 128.4, 128.4 (*o*-, *m*-Ph); 129.7 (C-5'); 137.8, 138.1, 138.1 (*i*-Ph); 138.6 (C-3'). MS, (CI, *iso*-butane), m/z (%): 473 (27) [M + H]⁺, 91 (100).

Anal. calcd for $C_{29}H_{32}N_2O_4(472.58)$: C, 73.71; H, 6.82; N, 5.93. Found: C, 73.75; H, 6.80; N, 5.84.

1,2,4-Tri-O-benzyl-1C-(1-methyl-1H-pyrazol-4-yl)-D-threitol (4b). The reaction of **1b** with methylhydrazine was carried out as described above for the preparation of **5a**. Compound **5b** was obtained as a colourless syrup. Yield 94 mg (88%); $[\alpha]_{D}^{25} - 51.2$ (c = 0.45, CHCl₃); $R_f 0.46$ (toluene/EtOAc 1:1). IR (film), ν (cm⁻¹): 3423 (OH). ¹H NMR (300.13 MHz, CDCl₃), δ 2.32 (br, 1H, OH-3); 3.44 (d, 2H, ³J_{3,4} = 5.7 Hz,

H-4a,b); 3.63 (dd, 1H, ${}^{3}J_{1,2} = 6.4$ Hz, ${}^{3}J_{2,3} = 3.2$ Hz, H-2); 3.79 (s, 3H, Me); 3.96 (dt, 1H, H-3); 4.25 (d, 1H, ${}^{2}J = 11.6$ Hz, CHHPh); 4.32, 3.34 (q(AB), 2H, ${}^{2}J = 8.5$ Hz, CH₂Ph); 4.41, 4.42 (q(AB), 2H, ${}^{2}J = 10.8$ Hz, CH₂Ph); 4.45 (d, 1H, ${}^{2}J = 11.6$ Hz, CHHPh); 4.51 (d, 1H, H-1); 7.03–7.07 (m, 2H, Ph); 7.15–7.29 (m, 13H, Ph); 7.23 (d, 1H, H-5'); 7.40 (d, 1H, ${}^{4}J_{3',5'} = 0.6$ Hz, H-3'). 13 C NMR (62.9 MHz, CDCl₃), δ 38.9 (Me); 69.7 (C-3); 70.5 (CH₂Ph); 71.0 (C-4), 73.4, 74.4 (CH₂Ph); 73.5 (C-1); 81.3 (C-2); 119.7 (C-4'); 127.6, 127.7, 128.1 (*p*-Ph); 127.8 (2x), 127.9, 128.3, 128.3 (2x) (*o*-, *m*-Ph); 129.6 (C-5'); 137.8, 137.9, 138.0 (*i*-Ph); 138.8 (C-3'). MS, (CI, *iso*-butane), *m*/*z* (%): 473 (71) [M + H]⁺, 91 (100).

Anal. calcd for C₂₉H₃₂N₂O₄(472.58): C, 73.71; H, 6.82; N, 5.93. Found: C, 73.48; H, 6.89; N, 5.84.

1,2,4-Tri-O-benzyl-1C-[1-(2-hydroxy-ethyl)-1H-pyrazol-4-yl]-D-erythritol (4c). A solution of **1a** (100 mg, 0.225 mmol) in ethanol (5 mL) and 2-hydrazinoethanol (0.031 mL, 0.45 mmol) were reacted as described for preparation of **5a**. The resulting residue was purified by column chromatography (chloroform/methanol 9:1). Compound **5c** was isolated as a colourless syrup.

Yield 101 mg (89%); $[\alpha]_D^{24} - 9.8$ (c = 1, CHCl₃); $R_f 0.34$ (chloroform/methanol 9:1). IR (film), ν (cm⁻¹): 3415 (OH). ¹H NMR (250.13 MHz, CDCl₃), δ 2.78 (br, 2H, OH-3, CH₂CH₂OH); 3.51 (m, 2H, H-4a,b); 3.60 (dd, 1H, ³J_{1,2} = 4.0 Hz, ³J_{2,3} = 7.0 Hz, H-2); 3.82-3.91 (m, 3H, H-3, CH₂CH₂OH); 4.10-4.15 (m, 2H, CH₂CH₂OH), 4.24 (d, 1H, ²J = 11.9 Hz, CHHPh); 4.36, 4.43 (q(AB), 2H, ²J = 11.3 Hz, CH₂Ph); 4.42 (s, 2H, CH₂Ph); 4.49 (d, 1H, ²J = 11.9 Hz, CHHPh); 4.62 (d, 1H, H-1); 7.08-7.14 (m, 2H, Ph); 7.16-7.30 (m, 13H, Ph); 7.32 (d, 1H, H-5'); 7.44 (d, 1H, ⁴J_{3',5'} = 0.9 Hz, H-3'). ¹³C NMR (62.9 MHz, CDCl₃), δ 53.7 (CH₂CH₂OH); 61.8 (CH₂CH₂OH); 70.3 (C-3); 70.8, 70.9 (C-4, CH₂Ph); 73.2 (C-1); 73.4, 74.2 (CH₂Ph); 81.1 (C-2); 118.7 (C-4'); 127.7-128.5 (Ph); 129.7 (C-5'); 137.6, 137.9, 137.9 (*i*-Ph); 139.0 (C-3'). MS, (CI, *iso*-butane), m/z (%): 503 (8) [M + H]⁺, 91 (100).

Anal. calcd for $C_{30}H_{34}N_2O_5(502.61)$: C, 71.69; H, 6.82; N, 5.57. Found: C, 71.30; H, 6.65; N, 5.40.

1,2,4-Tri-*O*-**benzyl-1***C*-**[1-(2-hydroxy-ethyl)-1***H*-**pyrazol-4-yl]-D**-**threitol (4d).** The reaction of **1b** with 2-hydrazinoethanol was carried out as described above for the preparation of **5c**. Compound **5d** was obtained as a colourless syrup. Yield 102 mg (90%); $[\alpha]_D^{22} - 36.1 \ (c = 1, \text{CHCl}_3)$; $R_f 0.34 \ (\text{chloroform/methanol 9:1})$. IR (film), $\nu \ (\text{cm}^{-1})$: 3415 (OH). ¹H NMR (250.13 MHz, CDCl}3), $\delta 2.78 \ (\text{br, 2H, OH-3}, \text{CH}_2\text{CH}_2\text{OH})$; 3.43 (dq, AB-part of ABX, 2H, ³ $J_{4a,4b} = 8.6$ Hz, H-4a,b); 3.64 (dd, 1H, ³ $J_{1,2} = 6.5$ Hz, ³ $J_{2,3} = 3.2$ Hz, H-2); 3.83–3.92 (m, 2H, CH₂CH₂OH); 3.96 (dt, 1H, ³ $J_{3,4a} = {}^{3}J_{3,4b} = 5.8$ Hz, H-3); 4.10–4.15 (m, 2H, CH₂CH₂OH); 4.27 (d, 1H, ²J = 11.6 Hz, CHHPh); 4.30, 4.33 (q(AB), 2H, ²J = 11.0 Hz, CH₂Ph); 4.40, 4.44 (q(AB), 2H, ²J = 12.0 Hz, CH₂Ph); 4.45 (d, 1H, ²J = 11.6 Hz, CHHPh); 4.53 (d, 1H, H-1); 7.01–7.07 (m, 2H, Ph); 7.16–7.30 (m, 13H, Ph); 7.32 (d, 1H, ⁴ $J_{3',5'} = 0.9$ Hz, H-5'); 7.46 (d, 1H, H-3'). ¹³C NMR (75.5 MHz, CDCl_3), δ 53.8 (CH₂CH₂OH); 61.8 (CH₂CH₂OH); 69.7 (C-3); 70.6 (CH₂Ph); 71.1 (C-4); 73.4 (CH₂Ph); 73.5 (C-1); 74.4 (CH₂Ph); 81.3 (C-2); 119.6 (C-4'); 127.6–128.4 (Ph); 129.8 (C-5'); 137.8, 137.9, 137.9 (*i*-Ph); 139.1 (C-3'). MS, (CI, *iso*-butane), m/z (%): 503 (17) [M + H]⁺, 91 (100).

Anal. calcd for C₃₀H₃₄N₂O₅(502.61): C, 71.69; H, 6.82; N, 5.57. Found: C, 71.30; H, 6.99; N, 5.58.

1*C*-(1-Methyl-1*H*-pyrazol-4-yl)-D-erythritol (5a). A suspension of 5a (300 mg, 0.630 mmol) and palladium over active carbon (10%) in anhydrous ethanol (10 mL) was stirred under a H₂-atmosphere. After 15 hr, the mixture was filtered over diatomite and then evaporated. Recrystallisation from ethanol yielded 6a as colourless crystals. Yield 125 mg (98%); mp 183–187°C; $[\alpha]_D^{23}$ –35.5 (*c* = 0.5, MeOH); *R*_f 0.26 (chloroform/methanol 2:1). IR (KBr), *v* (cm⁻¹): 3393, 3314, 3278 (OH). ¹H NMR (250.13 MHz, DMSO), δ 3.25–3.50 (m, 3H, H-2, H-3, H-4a); 3.56 (dd, 1H, ²*J*_{4a,4b} = 10.4 Hz, *J* = 2.5 Hz, H-4b); 3.76 (s, 3H, Me); 4.25–4.65 (br, 3H, 3x OH); 4.70 (br, 2H, H-1, OH); 7.30 (d, 1H, ⁴*J*_{3',5'} = 0.9 Hz, H-3'); 7.50 (d, 1H, H-5'). ¹³C NMR (62.9 MHz, DMSO), δ 38.5 (Me); 63.6 (C-4); 65.1 (C-1); 71.7 (C-3); 75.0 (C-2); 124.2 (C-4'); 129.0 (C-5'); 137.4 (C-3'). MS, (CI, *iso*-butane), *m/z* (%): 203 (22) [M + H]⁺, 185 (100) [M – H₂O]⁺.

Anal. calcd for $C_8H_{14}N_2O_4(202.21)$: C, 47.52; H, 6.98; N, 13.85. Found: C, 47.50; H, 7.02; N, 13.73.

1*C*-(1-Methyl-1*H*-pyrazol-4-yl)-D-threitol (5b). The deprotection of 5b was carried out as described above for the preparation of 6a. Recrystallisation from ethanol yielded 6b as colourless crystals. Yield 120 mg (94%); mp 53–55°C; $[\alpha]_D^{23} - 4.1$ (*c* = 0.5, H₂O); *R*_f 0.26 (chloroform/methanol 2 : 1). IR (KBr), *ν* (cm⁻¹): 3564, 3388, 3237 (OH). ¹H NMR (250.13 MHz, DMSO), δ 3.25–3.55 (m, 3H, H-2, H-4a,b); 3.72 (m, 1H, H-3); 3.77 (s, 3H, Me); 4.16 (d, 1H, ³*J* = 7.6 Hz, OH-2/4); 4.26 (d, 1H, ³*J*_{3,OH-3} = 5.8 Hz, OH-3); 4.45 (dd, 1H, ³*J*_{1,2} = 7.6 Hz, H-1); 4.45 (br, 1H, OH-2/4); 4.97 (d, 1H, ³*J*_{1,OH-1} = 5.6 Hz, OH-1); 7.29 (d, 1H, ⁴*J*_{3',5'} = 0.9 Hz, H-3'); 7.48 (d, 1H, H-5'). ¹³C NMR (75.5 MHz, DMSO), δ 38.5 (Me); 63.2 (C-4); 66.1 (C-1); 70.4 (C-3); 73.7 (C-2); 124.8 (C-4'); 129.0 (C-5'); 137.6 (C-3'). MS, (CI, *iso*-butane), *m/z* (%): 203 (60) [M + H]⁺, 185 (100) [M – H₂O]⁺.

Anal. calcd for C₈H₁₄N₂O₄(202.21): C, 47.52; H, 6.98; N, 13.85. Found: C, 47.14; H, 6.81; N, 13.67.

ACKNOWLEDGMENTS

The authors thank the Deutsche Forschungsgemeinschaft and the Fonds der Chemischen Industrie for financial support and Prof. Dr. J. Fernández-Beltrán and Dr. R. Baluja for their valuable comments. A. M. is grateful to the Deutscher Akademischer Austauschdienst for a scholarship.

REFERENCES

- Valpuesta Fernández, M.; López Herrera, F.J.; Gómez Pérez, C. Synthesis of methyl 2-deoxy-4,5:6,7-di-O-isopropylidene-D-arabino-hept-3-ulosonate and its use in the preparation of D-arabino-tetrahydroxybutyl-pyrimidine derivatives. Carbohyd. Res. 1983, 124, 333-337.
- Mancera, M.; Rodriguez, E.; Roffé, I.; Glabis, J.A.; Conde, C.F.; Conde, A. Stereoselective synthesis of nitropyrazolines: 1,3-dipolar cycloadition of diazoalkanes to

(*E*)-4,5,6,7,8-penta-*O*-acetyl-1,2,3-trideoxy-2-*C*-nitro-D-*manno*-oct-2-enitol. Carbohyd. Res. **1991**, *210*, 327–332.

- Mancera, M.; Rodriguez, E.; Roffé, I.; Glabis, J.A. Preparation of 1-bromo-1-nitro-D-galacto (and-D-manno)-hept-1-enitols and their 1,3-dipolar cycloaddition reactions with diazoalkanes. Carbohyd. Res. 1994, 253, 307–316.
- Bernal Montes, J.C.; Borrachero Moya, P.; Cabrera Escribano, F.; Gómez Guillen, M.; Madrid Díaz, F.; Moreno Martínez, J.M. 1,3 Dicarbonyl sugar derivatives from sugar nitro-olefins. Carbohyd. Res. 1996, 285, 49–58.
- Shafer, C.M.; Molinski, T.F. Synthesis of the C1–C9 core of Bengazole A: harnessing the ambident nucleophilicity of 2-lithiooxazole. Tetrahedron Lett. 1998, 39, 2903–2906.
- Alahiane, A.; Rochdi, A.; Taourirte, M.; Redwane, N.; Sebti, S.; Lazrek, H.B. Natural phosphate as lewis acid catalyst: a simple and convenient method for acyclonucleoside synthesis. Tetrahedron Lett. 2001, 42, 3579–3581.
- Sugimoto, T.; Ikemoto, K.; Murata, Sh.; Tazawa, M.; Nomura, T.; Hagino, Y.; Ichinose, H.; Nagtsu, T.; Wada, A. A convenient determination of chiral pteridines; application of fluorescented circular dichroism (FDCD) to the major pterin form *Escherichia coli*.. Heterocycles **2001**, *54*, 283–290.
- Kim, D.K.; Kim, Y.W.; Lee, N. Synthesis of 5-[2-(guanin-9-yl)- and 5-[2-(2-amino-purin-9-yl)ethyl]-2-D-*ribo*-(1',2',3'4'-tetrahydroxybutyl)-1,3-dioxane. J. Heterocycl. Chem. 2001, 38, 45-51.
- Ooi, H.Ch.; Marcuccio, S.M.; Jackson, W.R.; O'Keefe, D.F. Synthesis of the first sialic acid analogues containing a γ-pyrone moiety. Aust. J. Chem., 1999, 52, 1127–1130.
- Cavalheiro, A.J.; Yoshida, M. 6-[ω-Arylalkenyl]-5,6-dihydro-α-pyrones from cryptocarya moschata (Lauraceae). Phytochemistry, **2000**, *53*, 811–819.
- Ghosh, A.K.; Bilcer, G.A. Stereoselective synthesis of (+)-bronolide. Tetrahedron Lett. 2000, 41, 1003–1006.
- Rudloff, I.; Peseke, K.; Reinke, H. Synthesis of acyclo-C-nucleosides by ring transformation of 2(3)-formyl-glycals. J. Prakt. Chem. **1998**, *340*, 334–340.
- Rudloff, I.; Michalik, M.; Montero, A.; Peseke, K. A facile synthesis of acyclo-C-nucleoside analogues from 2(3)-formylglycals. Synthesis. 2001, 2001, 1686–1692.
- Montero, A.; Feist, H.; Michalik, M.; Quincoces, J.; Peseke, K. Synthesis of new acyclo-*C*-nucleoside analogues by ringtransformation of 2-formyl-glycals. Reactions with *C*,*N*-dinucleophiles.. Synthesis. 2002, 664–669.
- Montero, A.; Feist, H.; Michalik, M.; Quincoces, J.; Peseke, K. Synthesis of precursors for new pyrimidine acyclo-*C*-nucleoside analogues by ringtransformation of 2-formyl-galactal. J. Carbohyd. Chem. 2002, 305–312.
- Dieter, R.K. α-Oxoketene dithioacetals and related compounds: versatile three-carbon synthons. Tetrahedron. 1986, 42, 3029–3096.
- 17. Junjappa, H.; Ila, H.; Asokan, C.V. α-Oxoketene-*S*,*S*-, *N*,*S* and *N*,*N*-acetals: versatiles intermediates in organic synthesis. Tetrahedron. **1990**, *46*, 5423–5506.
- Peseke, K.; Thiele, G.; Michalik, M.; Powell, D.R. Anellation reactions of pyranose derivatives. Liebigs Ann./Recueil. 1997, 1019–1022.
- Ramesh, N.G.; Balasubramanian, K.K. Vilsmeier–Haack reaction of glycals: A short route to C-2-formyl glycals. Tetrahedron Lett. 1991, 32, 3875–3878.

Montero et al.

20. Freifelder, M., Ed.; Catalytic Hydrogenation in Organic Synthesis Procedures & Commentary; John Wiley & Sons, Inc.: New York, 1978; 109.

Received August 26, 2002 Accepted October 28, 2002